Back to Previous Page
Binh Dinh Pharmaceutical and Medical Equipment (DBD VN) – H1 2026 – Earnings Stabilize Ahead of Recovery
Summary of H1 2026 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN)
- Earnings remained broadly flat, reflecting a short-term period of increasing competition in key categories, particularly oncology and antibiotics, temporary delays in public-hospital tender activity following provincial mergers in mid-2025, and a slower-than-expected pace of new-product launches as DBD remained selective in API sourcing and prioritized supplier quality. On the topline, net revenue reached VND920bn (+0.5% y/y), as solid growth momentum in kidney dialysis products (+11.7% y/y), minerals, vitamins & supplements (+29.2% y/y), and psychiatric & neurological therapies (+18.0% y/y) offset declines in oncology products (-3.8% y/y) and antibiotics (-12.9% y/y). In terms of profitability, operating profit margin reduced to 19.1% (-1.7ppt y/y) amid more competitive tender pricing in the hospital channel. However, net financial income surged 129.2% y/y, partly cushioning the impact. As a result, net profit reached VND169bn (-1.1% y/y).
- Vietnam’s pharmaceutical market offers compelling growth potential, with specialized and higher-value prescription drugs expected to lead expansion at a 9.0% CAGR, while high-standard domestic manufacturers continue to benefit from favorable procurement policies, improving access to higher-tier tenders. Demand for advanced treatment categories such as vaccines, oncology, cardiovascular, and metabolic treatments continues to expand, supported by population aging and rising chronic-disease prevalence. Meanwhile, new policies are improving both diagnosis and treatment access, bringing more patients into formal treatment pathways. Since May 2026, Vietnam has introduced free annual health checks focused on non-communicable diseases. Around 30% of the population received health checks within the first month, suggesting a relatively fast initial rollout.
- For H2/2026, revenue is forecasted to be underpinned by double-digit growth in kidney dialysis solutions, continued contributions from DBD’s diversified portfolio and a recovery in oncology and antibiotics sales as hospital tender activity normalizes following temporary disruptions in H1. Full-year operating margin is projected to 18.0% (+0.5ppt y/y), supported by lower R&D-related cost allocation, while higher net financial income further lifts 2026F net profit.
- In the medium term, we expect revenue and earnings growth to accelerate, led by EU-GMP upgrades at the oncology plant in 2027 and aseptic injectable plant in 2029. Higher manufacturing standards should strengthen DBD’s position in higher-tier tenders, support better pricing and improve profit margins. Continued R&D and product launches should further broaden portfolio, while new production lines provide additional capacity. Against this backdrop, we project a 23.0% net profit CAGR over 2027–2030.
Interested in DBD? Click here to read more of our previous analysis on DBD’s quarterly earnings.
Read our latest insights in Vietnam Healthcare Sector here.
Company ratings and target prices are accessible for clients only.
If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.
Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.
Photo image credit: Bidiphar
